ViewRay Inc. (VRAY) shares plunged 6.95% in after-hours on Monday, January 24, 2022, and closed the daily trading at $4.15. However, in the regular trading session of Monday, VRAY’s stock gained 0.22%. VRAY shares have risen 0.90% over the last 12 months, and they have moved down 6.50% in the past week. Over the past three months, the stock has lost 34.51%, while over the past six months, it has declined 30.75%.
Let’s discuss its recent news and developments.
VRAY preliminary financial results
On January 10, 2022, ViewRay, Inc. (VRAY) announced preliminary financial results for the fourth quarter and full fiscal year ended December 31, 2021. The preliminary results have not been audited and are subject to change.
- VRAY’s total revenue for the fourth quarter of 2021 was approximately $20 million, compared to approximately $18 million in the fourth quarter of 2020.
- Total revenue for full-year 2021 was approximately $70 million compared to 2020 revenue of approximately $57 million.
- As of December 31, 2021, cash and cash equivalents were approximately $220 million.
VRAY participation in the recent event
ViewRay, Inc. (VRAY) recently participated in the 40th Annual J.P. Morgan Healthcare Conference which was held on January 13, 2022.
FDA clearance for VRAY MRIdian A3i
On December 15, 2021, ViewRay, Inc. (VRAY) received FDA 510(k) clearance for its next generation of MRI-guided radiation therapy features, focused on enhancing on-table adaptive workflow and expanding clinical utility. MRIdian A3i includes a suite of new features to streamline on-table adaptive workflow and provide the potential to reduce treatment times, along with a new brain treatment package expanding clinical utility into cranial stereotactic radiosurgery (SRS) and stereotactic radiation therapy (SRT).
VRAY MRIdian system chosen by Northside Hospital
On December 7, 2021, ViewRay, Inc. (VRAY) was chosen by Northside Hospital in Georgia for MRIdian MRI-guided radiation therapy system to expand radiation therapy treatment services at its Northside Hospital Cancer Institute in Atlanta.
Northside Hospital Cancer Institute is the largest and most comprehensive cancer network in Georgia. It has 55 cancer centers at multiple locations across Georgia, which allows patients to receive the most advanced treatments close to home.
The MRIdian system provides oncologists outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to target cancer with the patient on the table.
Earlier on November 24, 2021, ViewRay, Inc. announced, that more than 2,300 pancreatic cancer patients have been treated with MRIdian at 46 centers around the world.
Well, as of this writing, we have no latest news or development which could be linked with its poor performance in the after-hours on Monday. Let’s see how it performs on Tuesday?